Q&M 1H2023 Core Healthcare Revenue stays resilient as the Group focuses on organic growth plans
- Core Healthcare Business[1] revenue remains resilient and the Group has a healthy net cashflow from operating activities for 1H23 of $14.2 million, providing cash resources for sustainable growth. - Well-positioned to cater to the rising demand for primary and high value specialist dental healthcare services through network expansion and optimisation of the Group's Artificial Intelligence system. - 1st interim dividend of 0.16 cents per shares to be paid on 13 September 2023.
SINGAPORE, Aug 15, 2023 - (ACN Newswire) - Mainboard-listed Q&M Dental Group (Singapore) Limited ("Q&M", the "Company", and together with its subsidiaries, the "Group") today reported total revenue of S$87.1 million, and profit after tax attributable to parent of S$5.3 million for the first half ended 30 June 2023 ("1H2023"). The Group's earnings before interest, tax, depreciation, amortisation ("EBITDA") for 1H2023 was S$18.5 million.
Core Healthcare Business revenue decreased marginally from S$83.7 million for 1H2022 to S$83.3 million for 1H2023, mainly due to higher revenue contribution from Singapore dental clinics offset by lower revenue contribution from Singapore medical clinics and the impact of the weakening Malaysian Ringgit for the Group's operations in Malaysia. The Group's other business segment ie medical laboratory were impacted by lower demand for Covid-19 testing.
Dr Ng Chin Siau, Group Chief Executive Officer of Q&M, said, "The continual resilience of Q&M's Core Healthcare Business is well appreciated by investors and reflects the Group's well-established foundations. Further, we will focus on organic growth following significant expansion of our dental clinic network across Singapore and Malaysia in 2022. We will continue to invest in technology and implement strategies that will enable us to further optimise productivity across our clinic network."
Recently, Q&M launched its dedicated mobile App on both the Apple Appstore and Google Play. With just the click of a few buttons, a patient can select their preferred date, time and clinic location to make appointments to see the dentist. Q&M's patients can receive timely reminders before the appointment dates and view past and future appointments, reschedule or cancel appointments anytime, as well as manage their digital receipts through the App. Additionally, results of x-rays taken are uploaded into the App for quick reference. The patient will receive a 6-monthly reminder notification when it is time for them to attend their dental check-up, so as to ensure their dental and oral conditions are closely monitored.
Looking ahead
Q&M Group has devised a holistic strategy to foster sustainable growth focusing on organic growth by leveraging on our brand and expertise and capitalising on opportunities to expand our services and reach.
We are working hard to build a strong platform upon which our future growth can be firmly established based on the following 5 thrusts:
1. Building Strong Foundations- strengthening the basics
Our cluster management system is being enhanced with dentists and dental assistants working even more closely together with area managers to optimise both human and physical resource allocation throughout the network.
2. Improving efficiency - reducing costs and wastage
Our Group is mindful of keeping costs low and using central purchasing as much as possible to reduce wastage and ensure more just-in-time ordering so that we can also reduce storage costs correspondingly.
3. Medical Laboratory
Post-pandemic, the Group's medical laboratory business, Acumen Diagnostic will continue to develop its range of tests and solutions to maximise its intellectual property and research capabilities for various medical purposes. These include the tests for sepsis, identification of bacteria pathogens and their associated antimicrobial resistance in hospitalised pneumonia.
4. Expanding our brand- locally and overseas
Beyond Singapore, the Group continues to explore good opportunities to develop a new sustainable growth pillar through organic growth and further expansion of its dental business in Southeast Asia growing private dental healthcare market. We are also exploring the expansion of the Q&M brand and knowhow beyond our current borders. As a premium dental group with a strong reputation for high-quality products and services, we are working towards exporting our expertise regionally and beyond in a deliberate and decisive manner.
Commitment to our Community
Anchored in the Company's philosophy, Q&M Free Dental Clinic Limited, a registered charity under the Commission of Charities, opened its first free dental clinic on 10 July 2023 in Chai Chee, to provide essential dental treatment for the underprivileged individuals and families in need.
This press release is read in conjunction with Q&M's 1H2023 results release on SGXNET.
For more information, please read the attached SGXNET announcement and media release.
https://links.sgx.com/1.0.0/corporate-announcements/N9238L5A9JUG97NG/ca70061aa798c196bcb9132653f9e01c12ad35d1d3327823f3a120d1949a5e95
[1] Core Healthcare Business excludes contributions from the Group?s medical laboratory and expenses incurred on the development of the Group?s digital Artificial Intelligence (AI) guided clinical decision support system as well as rental rebates received from the Singapore Government. About Q&M Dental Group (Singapore) Limited (QC7.SI)
Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.
The Group owns the largest network of private dental outlets in Singapore, operating 108 dental outlets across the country. Underpinned by about 270 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.
Outside of Singapore, the Group has 44 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north-eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.
The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.
In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Currently, Acumen focuses on developing its range of medical research, tests and solutions to secure viable patents and to achieve successful commercialisation of the medical products in the near future.
The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009.
For more information on the Group, please visit www.QandMDental.com.sg
For more information, please contact: Waterbrooks Consultants Pte Ltd Wayne Koo: wayne.koo@waterbrooks.com.sg, +65 9338-8166 Derek Yeo: derek@waterbrooks.com.sg, +65 9791-4707 General: query@waterbrooks.com.sg, +65 9690-4959
Proud Investor Relations partner: https://www.waterbrooks.com.sg/ and https://www.shareinvestorholdings.com/
Source: Q&M Dental Group Ltd Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm, Local Biz
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market Nov 27, 2024 05:53 JST
| TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025 Nov 26, 2024 17:55 JST
| Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan Nov 26, 2024 15:50 JST
| Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues Nov 26, 2024 10:51 JST
| TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025 Nov 25, 2024 17:10 JST
| Toyota Submits Progress Report on Recurrence Prevention Measures Nov 25, 2024 15:43 JST
| TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market Nov 25, 2024 15:00 JST
| MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant Nov 25, 2024 14:18 JST
| Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship Nov 25, 2024 11:55 JST
| Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025 Nov 22, 2024 11:00 JST
| NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth Nov 21, 2024 22:59 JST
| Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan Nov 21, 2024 15:35 JST
| Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP Nov 21, 2024 09:00 JST
| ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study Nov 20, 2024 23:05 JST
| Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center Nov 20, 2024 15:30 JST
| Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan Nov 20, 2024 11:51 JST
| Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements Nov 20, 2024 10:24 JST
| Kingsoft Announces 2024 Third Quarter Results Nov 19, 2024 18:54 JST
| NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System Nov 19, 2024 15:30 JST
| Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings Nov 19, 2024 09:02 JST
|
More Latest Release >>
|